MTM Laboratories (Germany) a commercial-stage molecular diagnostics company focused on cervical cancer, closed on an $10M bringing the Series C financing to $56M. Participants includeGilde Healthcare Partners , LBBW Venture Capital, HBM BioVentures, and HBM BioCapital.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb